Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 8:15:1509987.
doi: 10.3389/fimmu.2024.1509987. eCollection 2024.

The immunological bases of alemtuzumab as induction-therapy in pediatric-onset multiple sclerosis

Marco Puthenparampil  1   2   3 , Marta Gaggiola  1   2 , Francesca Rinaldi  2 , M Nosadini  3   4 , S Sartori  3   4 , Paola Perini  2 , Paolo Gallo  1   2
Affiliations
Review

The immunological bases of alemtuzumab as induction-therapy in pediatric-onset multiple sclerosis

Marco Puthenparampil et al. Front Immunol. .

Abstract

Pediatric-Onset Multiple Sclerosis (POMS) is characterized by both white and grey matter inflammation, as well as by a higher risk of long-term physical and cognitive disability. The peculiar immunopathogenic mechanisms of POMS suggests that the use of induction therapies, including alemtuzumab (ALTZ), might be a promising approach, at least for postpuberal (> 11 yo) POMS. Although no data on the use of induction therapies in POMS are available from clinical trials currently, case series or case reports on the effect of alemtuzumab (ALTZ) have been recently published. In this review we have briefly revised the immunopathogenic features of POMS, as well as on how ALTZ might impact on them, reporting its efficacy observed in different POMS cohorts.

Keywords: POMS; alemtuzumab; induction therapy; multiple sclerosis; pediatric-onset MS.

PubMed Disclaimer

Conflict of interest statement

MP, report grants from Almirall, Teva, Sanofi Genzyme, Merck Serono, Biogen Italy, Novartis; consultancy for Novartis, Biogen Italy, Sanofi Genzyme; board membership Sanofi Genzyme, Novartis, Biogen Italy, and Sandoz. FR report grants from Almirall, Teva, Sanofi Genzyme, Merck Serono, Biogen Italy, Novartis; consultancy for Novartis, Biogen Italy, Sanofi Genzyme. PP reports grants from Almirall, Teva, Sanofi Genzyme, Merck Serono, Biogen Italy, Novartis, Roche; consultancy for Novartis, Biogen Italy, Sanofi Genzyme, Roche. PG reports grant from Almirall, Teva, Sanofi Genzyme, Merck Serono, Biogen Italy, Novartis, Roche, Bristol Myers Squibb; consultancy for Novartis, Biogen Italy, Sanofi Genzyme, Roche, Bristol Myers Squibb; board membership Sanofi Genzyme, Novartis, Biogen Italy, Roche, Merck Serono, Bristol Myers Squibb. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

References

    1. Bigi S, Banwell B. Pediatric multiple sclerosis. J Child Neurol. (2012) 27:1378–83. doi: 10.1177/0883073812452784 - DOI - PubMed
    1. Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D, Hashimoto S, et al. . Early onset multiple sclerosis: A longitudinal study. Neurology. (2002) 59:1006–10. doi: 10.1212/WNL.59.7.1006 - DOI - PubMed
    1. Ghezzi A, Deplano V, Faroni J, Grasso MG, Liguori M, Marrosu G, et al. . Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler. (1997) 3:43–6. doi: 10.1177/135245859700300105 - DOI - PubMed
    1. Bellantonio P, Iuliano G, Di Blasio F, Ruggieri S. Prevalence and incidence of multiple sclerosis in campobasso (Molise region chieftown, southern Italy). Clin Neurol Neurosurg. (2013) 115:1806–8. doi: 10.1016/j.clineuro.2013.05.001 - DOI - PubMed
    1. Ghezzi A, Pozzilli C, Liguori M, Marrosu MG, Milani N, Milanese C, et al. . Prospective study of multiple sclerosis with early onset. Mult Scler. (2002) 8:115–8. doi: 10.1191/1352458502MS786OA - DOI - PubMed

LinkOut - more resources